Liss' Lowdown #21

Liss' Lowdown #21

Preclinical Breakthrough of the month:

Diversifying Preclinical Research: AMSBIO's Role in Addressing Gender Discrepancies and Advancing Inclusivity

AMSBIO expands its offerings to support researchers in diversifying preclinical models, aiming to address gender gaps pervasive in research. Despite advancements in clinical trials, inclusivity in preclinical research remains overlooked, leading to critical knowledge gaps in treatment effects across populations. In a blog marking International Women's Day, AMSBIO proposes an intestinal organoid biobank to improve accessibility and highlights gender reporting disparities in COVID-19 vaccine development. As a global biospecimen provider, AMSBIO offers a diverse biorepository and custom tissue procurement service to meet specific research needs. Partnering with ScreenIn3D (S3D), AMSBIO leverages novel organoids and lab-on-a-chip technology to aid researchers in cost-effective high-throughput assays. CEO Alex Sim notes the FDA's 2023 legislation, mandating demographic requirements in clinical trials, and underscores AMSBIO's role in supporting research for societal benefit and the development of combination therapies.

Clinical Breakthrough of the month:

Promising Gene Therapy for Giant Axonal Neuropathy Shows Safety and Potential Benefits in NIH-led Trial

A gene therapy trial targeting giant axonal neuropathy (#GAN), a fatal childhood neurodegenerative disease, showed promising results in a study led by the The National Institutes of Health . The therapy, scAAV9/JeT-GAN, delivered functional copies of the defective GAN gene directly into spinal fluid. Results, published in the New England Journal of Medicine, indicated the treatment was well tolerated and slowed motor function decline in some patients. Notably, sensory nerve regeneration occurred in several cases. The trial, involving 14 children aged 6 to 14, revealed a favorable safety profile with few adverse events. The therapy's efficacy increased with higher doses, offering hope for GAN patients and potentially informing gene therapy for other diseases. Future research will explore treatment effectiveness in younger patients and those in earlier disease stages. Supported by various organizations, including NINDS and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, this trial represents a collaborative effort to advance therapies for rare diseases.

Partnership of the month:

Strategic Partnership Enhances Drug Development: InnoSer and CR2O Set New Industry Standard

InnoSer and CR2O | Clinical CRO collaborate to provide a comprehensive drug development solution, bridging pre-clinical and clinical phases. This partnership aims to streamline the process, reduce costs, and mitigate risks, setting a new industry standard. Clients benefit from an integrated service spanning early-stage discovery to phase I-IV trials, with specialized offerings such as toxicology, pharmacology, and regulatory strategy. By combining expertise, the companies empower researchers with enhanced efficiency and regulatory insights, aligning with their commitment to innovation and patient care. Jan Bartels , CEO of InnoSer, emphasizes the partnership's focus on advancing patient care and excellence in research services. CR2O CEO Hadil Es-Sbai highlights the importance of integrating R&D processes to address industry fragmentation. Together, InnoSer and CR2O aim to offer validated drug development pathways, increasing client confidence and driving innovation in the sector. This strategic collaboration signifies a shift towards a more cohesive and efficient approach to drug development, benefitting both researchers and patients alike.


To view or add a comment, sign in

More articles by Elissa Buxton

  • Liss' Lowdown #31

    Liss' Lowdown #31

    Preclinical Breakthrough of the month: Neuroactive Drugs Show Promise in Preclinical Glioblastoma Treatment A recent…

  • Liss' Lowdown #30

    Liss' Lowdown #30

    Preclinical Breakthrough of the month: Lab-Grown Intestines Reveal Two Subtypes of Crohn's Disease, Paving the Way for…

    1 Comment
  • Liss' Lowdown #29

    Liss' Lowdown #29

    Preclinical Breakthrough of the month: Plasma Tau Test Shows Promise for Early Alzheimer's Detection A study presented…

    1 Comment
  • Liss' Lowdown #28

    Liss' Lowdown #28

    Preclinical Breakthrough of the month: New Treatment Approach Shows Promise Against Hard-to-Treat Breast Cancer…

  • Liss' Lowdown #27

    Liss' Lowdown #27

    Preclinical Breakthrough of the month: Gene-Editing Therapy Targets Lung Cells in Cystic Fibrosis Study A recent…

  • Liss' Lowdown #26 - 1000 Subscribers!

    Liss' Lowdown #26 - 1000 Subscribers!

    Preclinical Breakthrough of the month: Breakthrough in Herpes Cure: Gene Therapy Shows 90% Reduction in Preclinical…

    5 Comments
  • Liss' Lowdown #25

    Liss' Lowdown #25

    Preclinical Breakthrough of the month: MIRA Pharmaceuticals Advances Ketamir-2 for Mental Health and Pain Relief MIRA…

  • Liss' Lowdown #24

    Liss' Lowdown #24

    Preclinical Breakthrough of the month: Capsida Biotherapeutics Advances Next-Generation Gene Therapy for Parkinson’s…

    2 Comments
  • Liss' Lowdown #23

    Liss' Lowdown #23

    Preclinical Breakthrough of the month: Charles River Laboratories Launches AMAP Initiative to Reduce Animal Testing in…

    4 Comments
  • Liss' Lowdown #22

    Liss' Lowdown #22

    Preclinical Breakthrough of the month: Unveiling Substance Influence on Brain Cell Connections: A Preclinical…

Insights from the community

Others also viewed

Explore topics